IRIS - Res&Arch Institutional Research Information System - Research & Archive

SPORTOLETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.929
AS - Asia 4.052
EU - Europa 3.367
SA - Sud America 657
Continente sconosciuto - Info sul continente non disponibili 453
AF - Africa 111
OC - Oceania 6
Totale 13.575
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.746
SG - Singapore 1.886
IT - Italia 1.062
CN - Cina 589
IE - Irlanda 579
BR - Brasile 498
HK - Hong Kong 476
VN - Vietnam 405
RU - Federazione Russa 400
DE - Germania 240
FR - Francia 199
FI - Finlandia 170
SE - Svezia 138
KR - Corea 132
UA - Ucraina 131
GB - Regno Unito 121
BD - Bangladesh 114
IN - India 110
CA - Canada 85
MX - Messico 60
AR - Argentina 58
RO - Romania 53
TR - Turchia 50
NL - Olanda 47
AT - Austria 44
IQ - Iraq 35
UZ - Uzbekistan 35
BE - Belgio 33
PL - Polonia 32
PK - Pakistan 30
ZA - Sudafrica 28
JP - Giappone 25
ES - Italia 23
CZ - Repubblica Ceca 22
ID - Indonesia 22
PH - Filippine 22
CO - Colombia 21
EC - Ecuador 19
CH - Svizzera 18
LT - Lituania 17
SA - Arabia Saudita 17
VE - Venezuela 16
EG - Egitto 15
PE - Perù 15
JO - Giordania 12
MA - Marocco 11
CL - Cile 10
ET - Etiopia 9
AZ - Azerbaigian 8
KE - Kenya 8
MY - Malesia 8
UY - Uruguay 8
CI - Costa d'Avorio 7
IL - Israele 7
IR - Iran 7
KZ - Kazakistan 7
LB - Libano 7
NI - Nicaragua 7
NP - Nepal 7
PT - Portogallo 7
PY - Paraguay 7
TH - Thailandia 7
TN - Tunisia 7
AL - Albania 6
JM - Giamaica 6
SC - Seychelles 6
BO - Bolivia 5
CR - Costa Rica 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
DO - Repubblica Dominicana 4
PA - Panama 4
AO - Angola 3
AU - Australia 3
GE - Georgia 3
GR - Grecia 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
DZ - Algeria 2
EU - Europa 2
IM - Isola di Man 2
KH - Cambogia 2
LV - Lettonia 2
MK - Macedonia 2
NG - Nigeria 2
OM - Oman 2
SN - Senegal 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UG - Uganda 2
AM - Armenia 1
Totale 13.102
Salva come PNG Salva come JPEG
Città #
Singapore 1.396
Chandler 594
Dublin 572
San Jose 553
Perugia 489
Hong Kong 472
San Mateo 384
Ashburn 329
Boardman 207
Santa Clara 206
Dong Ket 140
Altamura 131
Lauterbourg 131
Moscow 129
Seoul 129
Munich 117
Beijing 112
Medford 108
Princeton 105
Lawrence 101
New York 92
Los Angeles 90
Ho Chi Minh City 87
Ann Arbor 81
Hanoi 66
Wilmington 66
Andover 63
Helsinki 63
Jacksonville 59
Piscataway 56
Turku 56
The Dalles 49
São Paulo 46
Bucharest 44
Rome 37
Brussels 33
Council Bluffs 33
Houston 33
Dallas 31
Des Moines 28
Brooklyn 27
Frankfurt am Main 27
Dearborn 26
Montreal 26
Milan 25
Nuremberg 25
Redmond 25
Shanghai 25
Tokyo 25
Mexico City 24
Foligno 23
Orem 23
Vienna 23
Tashkent 22
Warsaw 22
Amsterdam 21
Hefei 21
Toronto 21
Belo Horizonte 20
London 20
San Paolo di Civitate 20
Rio de Janeiro 19
Norwalk 18
Atlanta 17
Chennai 17
Chicago 17
Redwood City 17
Barnet 16
Phoenix 16
Assisi 15
Haiphong 15
San Francisco 15
Buffalo 14
Izmir 14
Manchester 14
Saint Petersburg 14
Stockholm 14
Baghdad 13
Denver 13
Johannesburg 13
Ankara 12
Charlotte 12
Guangzhou 12
Menlo Park 12
Mumbai 12
Amman 11
Brno 11
Philadelphia 10
Falkenstein 9
Istanbul 9
Paris 9
Poplar 9
Woodbridge 9
Changsha 8
Collazzone 8
Falls Church 8
Jakarta 8
Lima 8
Manila 8
Quito 8
Totale 8.493
Salva come PNG Salva come JPEG
Nome #
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 183
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 183
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 181
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 180
BCOR gene alterations in hematological diseases 177
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis 167
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 164
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 163
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 158
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 155
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 144
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 144
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 138
Mutant NPM1 Maintains the Leukemic State through HOX Expression 135
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 134
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 132
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 132
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 132
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 131
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 130
Wnt/beta-Catenin Signaling Induces Integrin alpha 4 beta 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice 130
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL 129
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 128
Mesenchymal cells: a vehicle for gene therapy 127
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 126
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 124
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 122
Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 120
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 118
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 118
The radiosensitizer Silver nanoparticles effects are prevent to ion channel blocker DIDS in U251 human glioblastoma cell line. 116
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 116
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. 115
Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice 113
T regulatory cell separation for clinical application. 113
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 111
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 110
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 110
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 110
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 110
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 110
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 110
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 109
BRAF mutations in hairy-cell leukemia. 109
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 109
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 109
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 109
Isolation and characterization of a new human T regulatory cell subset from peripheral blood CD4+ T lymphocyte 108
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 107
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 106
Richter's transformation in the heart 105
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice 104
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL 103
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 102
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 100
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 99
Synthesis and characterization of UiO-66 metal-organic frameworks nanoparticles and their evaluation as drug delivery carriers in U251 glioblastoma cells 98
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 98
Functions of the native NPM1 protein and its leukemic mutant 97
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 96
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 96
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 95
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 95
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells 94
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 93
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 93
A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect 91
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 91
Glucocorticoidi-Induced TNFR family Related gene (GITR) enhances dendritic cell activity 90
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia 89
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 89
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 89
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 89
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 86
Mesenchymal cells recruit and regulate T regulatory cells. 85
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 84
NPM1-mutated acute myeloid leukemia: from bench to bedside 83
FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia 82
Catalase prevents DNA damage and cationic current activation by silver nanoparticles in U251 human glioblastoma cell line 82
Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. 81
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 81
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 80
A DYSREGULATED, DRUGGABLE PP2A/AKT/GSK3 beta AXIS SUSTAINS NOTCH1 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 79
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports 78
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 78
Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies 76
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. 76
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 75
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 74
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 74
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 72
NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential 71
A scale of "bad" co-mutations in NPM1-driven AML 71
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. 69
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study 68
The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model 68
Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia. 68
The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein 67
Starry sky pattern predicts RAS pathway activation in NPM1‐mutated acute myeloid leukemia 67
The landscape of BRAF transcript and protein variants in human cancer. 67
Totale 10.753
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.124
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.124
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.264 0 376 9 44 26 9 18 226 30 138 210 178
2022/20231.946 111 371 18 183 140 195 11 85 708 8 81 35
2023/2024918 40 81 52 35 6 24 282 10 52 31 137 168
2024/20252.398 77 195 63 81 293 142 211 172 478 109 366 211
2025/20265.286 360 303 237 597 741 482 902 324 554 491 159 136
2026/2027311 151 160 0 0 0 0 0 0 0 0 0 0
Totale 13.575